Illumina, Inc 8-K, filed Jun 13, 2023
Illumina, Inc. (ILMN)
8-K
2023-06-13
For: 2023-06-08
View Original
Added on
April 12, 2026
About this 8-K
Illumina, Inc filed this 8-K on June 13, 2023, reporting on events of June 8, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 8, 2023
(Exact name of registrant as specified in its charter)
(Commission File Number)
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
(I.R.S. Employer
Identification No.)
|
(Address of principal executive offices) (Zip code)
(858 ) 202-4500
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of
each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13a of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On June 11, 2023, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) accepted the resignation of Francis deSouza, which Mr. deSouza
submitted to the Board on June 8, 2023, as Chief Executive Officer and as a director of the Company, effective immediately, and the Board appointed Charles Dadswell, the Company’s current Senior Vice President and General Counsel, to serve as interim
Chief Executive Officer, effective immediately, until the Board’s search for a permanent Chief Executive Officer is completed. Mr. Dadswell will also continue to serve as the Company’s Senior Vice President and General Counsel. Mr. deSouza will
continue to serve in an advisory capacity to the Company until July 31, 2023. Accordingly, the Board reduced its size to ten (10) members.
Mr. Dadswell, 65, has served as Senior Vice President and General Counsel of the Company since April 2013. At this time, the Company has not entered
into, amended, or modified any plan, contract, agreement, grant or award in connection with the Board’s appointment of Mr. Dadswell to serve as interim Chief Executive Officer. Mr. Dadswell has no family relationship with any directors or executive
officers of the Company, nor are there any arrangements or understandings between Mr. Dadswell and any other persons pursuant to which he was selected as an officer of the Company. There are no related party transactions between Mr. Dadswell and the
Company reportable under Item 5.02 of Form 8-K and Item 404(a) of Regulation S-K.
A copy of the press release announcing the Company’s Chief Executive Officer transition plan is attached as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Date: June 13, 2023
|
ILLUMINA, INC.
|
|
|
By:
|
/s/ CHARLES DADSWELL
|
|
Name:
|
Charles Dadswell
|
|
Title:
|
Interim Chief Executive Officer, General Counsel & Secretary
|
Exhibit 99.1
Illumina announces CEO transition plan
SAN DIEGO, June 11, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its Board of
Directors has accepted the resignation of Francis deSouza as Illumina's Chief Executive Officer and as a Director, effective Sunday, June 11. Charles Dadswell, Senior Vice President and General Counsel, has been named interim CEO while the Board of
Directors conducts a search for a new CEO. Mr. deSouza will stay on in an advisory capacity until July 31, 2023.
Illumina's Board said it is appreciative of Mr. deSouza's contributions and commitment to the company and all of its stakeholders.
"We thank Francis for his contributions and leadership, and are very excited about embarking on the next chapter of Illumina's great journey," said Stephen P. MacMillan,
Chair of the Board of Illumina. "Illumina's technology remains at the forefront of DNA sequencing and has continued to set the pace for the industry. We are confident Illumina can continue to execute on its goals while we conduct and complete a CEO
search process."
"It has been the privilege of a lifetime to serve Illumina. When I joined this company in 2013, we talked about making the company more clinical, more digital, and more
global. On behalf of patients, clinicians and physicians everywhere, I'd like to thank the thousands of Illumina employees who made it happen," said Mr. deSouza. "We have made great progress together, but I believe we are still at the very beginning
of the impact Illumina will have on human health by unlocking the power of the genome."
The Board of Directors is conducting a search for a new CEO looking at internal and external candidates. The Board is focused on finding a world-class business leader who
can drive advancements in healthcare, growth and shareholder value.
Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding
mandates, the future, business plans and other statements that are not historical in nature. These statements are made on the basis of Illumina's views and assumptions regarding future events and business performance and plans as of the time the
statements are made. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "project," "target," "will" and other words and terms
of similar meaning. Illumina does not undertake any obligation to update these statements unless required by applicable laws or regulations, and you should not place undue reliance on forward-looking statements. Specific factors are set forth in
Illumina's Annual Report on Form 10-K for the year ended January 1, 2023 under the caption "Risk Factors", in information disclosed in public conference calls, the date and time of which are released beforehand, and in filings with the Securities and
Exchange Commission including, among others, quarterly reports on Form 10-Q.
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
David McAlpine
347-327-1336
PR@illumina.com
David McAlpine
347-327-1336
PR@illumina.com